Med-IQ
Increasing Physician Awareness of Pulmonary Arterial Hypertension in Systemic Sclerosis
E-Publication E-Publication

Increasing Physician Awareness of Pulmonary Arterial Hypertension in Systemic Sclerosis


Time to Complete:
30 minutes
Released:
7/14/17
Expires:
7/13/18

Maximum Credits:

0.5 AMA PRA Category 1 Credit(s)
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.

E-Publication E-Publication
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.
Time to Complete:
30 minutes

Released:
7/14/17

Expires:
7/13/18

Maximum Credits:
0.5 AMA PRA Category 1 Credit(s)
Share on:
E-Publication E-Publication
By clicking "Start," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Policy and Terms of Service.

Share on:


Time to Complete:
30 minutes
Released:
7/14/17
Expires:
7/13/18


Maximum Credits:
0.5 AMA PRA Category 1 Credit(s)


Overview: This online CME publication discusses guideline recommendations for pulmonary arterial hypertension (PAH) screening in patients with systemic sclerosis (SSc) and presents key insights on available treatment options for PAH. In addition, this publication is enhanced with audio clips from an expert roundtable discussion on the increased risk of PAH in SSc, signs and symptoms that should prompt further evaluation for PAH, and the importance of communication among the multidisciplinary team.

Faculty

Lorinda Chung, MD, MS

Associate Professor of Medicine (Immunology and Rheumatology) and Dermatology

Stanford University School of Medicine

Stanford, CA

Ronald Oudiz, MD, FACP, FACC, FCCP

Professor of Medicine

David Geffen School of Medicine

University of California, Los Angeles

Director, Liu Center for Pulmonary Hypertension

Los Angeles Biomedical Institute at Harbor-UCLA Medical Center

Los Angeles, CA


Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.


Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.  

Lorinda Chung, MD, MS
Consulting fees/advisory boards: Actelion Pharmaceuticals Ltd., Reata Pharmaceuticals, Inc.
Contracted research: Bayer HealthCare Pharmaceuticals, United Therapeutics Corporation
 
Ronald Oudiz, MD, FACP, FACC, FCCP
Consulting fees/advisory boards: Actelion Pharmaceuticals Ltd., Bayer HealthCare Pharmaceuticals, Gilead Sciences, Inc., Reata Pharmaceuticals, Inc., SteadyMed Therapeutics, Inc., United Therapeutics Corporation
Fees received for promotional/non-CME activities: Actelion Pharmaceuticals Ltd., Bayer HealthCare Pharmaceuticals, Gilead Sciences, Inc., United Therapeutics Corporation
Contracted research: Actelion Pharmaceuticals Ltd., Arena Pharmaceuticals Inc., Bayer HealthCare Pharmaceuticals, Eiger BioPharmaceuticals, Gilead Sciences, Inc., Reata Pharmaceuticals, Inc., SteadyMed Therapeutics, Inc., United Therapeutics Corporation

Laura Trimingham, MD
Ownership interest (stocks/stock options – excluding mutual funds): Juno Therapeutics
 
The peer reviewers and other activity planners have no financial relationships to disclose.


This activity has been approved for AMA PRA Category 1 Credit™.


This activity is supported by an educational grant from Gilead Sciences, Inc.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or e-mail info@med-iq.com. For technical assistance, please refer to our support manual.